Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
Cancer company reports Q2 revenues of $212,000, down from same time last year
September 9th, 2004
Dendreon Corp. (DNDN) reported results for the quarter ended June 30, 2004. Revenues for the second quarter of 2004 were $212,000 compared to $1.8 million for the quarter ended June 30, 2003. The decrease in revenue for the quarter ended June 30, 2004 was attributable to the termination of Dendreon's collaboration with Kirin Brewery Co., Ltd., in November 2003. Revenues for the six months ended June 30, 2004 were $4.9 million compared to $3.6 million for the six months ended June 30, 2003. Revenues in the six months ended June 30, 2004 were primarily from Dendreon's license agreement with Nuvelo, Inc., for Dendreon's novel anticoagulant, recombinant...
Source: Blood Weekly (2004-09-09)
|
